EDITAS MEDICINE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.32 USD | +1.92% |
|
-3.10% | -47.48% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,502 | 4,335 | 1,796 | 596.6 | 827.4 | 437.5 | - | - |
| Enterprise Value (EV) 1 | 1,045 | 3,932 | 1,296 | 159.2 | 400.2 | 185 | 342.5 | 350.8 |
| P/E ratio | -11 x | -35.4 x | -9.32 x | -2.76 x | -5.01 x | -2.17 x | -2.08 x | -2.04 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 73.1 x | 47.8 x | 70.3 x | 30.3 x | 10.6 x | 12.8 x | 17.6 x | 6.74 x |
| EV / Revenue | 50.9 x | 43.3 x | 50.7 x | 8.08 x | 5.12 x | 5.4 x | 13.8 x | 5.41 x |
| EV / EBITDA | -7.56 x | -30 x | -6.89 x | -0.72 x | -2.45 x | -0.8 x | -1.25 x | -1.34 x |
| EV / FCF | -18.6 x | -21 x | -7.55 x | -0.88 x | -2.92 x | -0.95 x | -1.49 x | -1.35 x |
| FCF Yield | -5.38% | -4.76% | -13.3% | -114% | -34.2% | -105% | -67.2% | -73.9% |
| Price to Book | 6.16 x | 11.1 x | 3.28 x | 1.69 x | 2.2 x | 1.74 x | 3.81 x | 5.48 x |
| Nbr of stocks (in thousands) | 50,716 | 61,824 | 67,648 | 67,259 | 81,674 | 82,235 | - | - |
| Reference price 2 | 29.61 | 70.11 | 26.55 | 8.870 | 10.13 | 5.320 | 5.320 | 5.320 |
| Announcement Date | 2/26/20 | 2/25/21 | 2/24/22 | 2/22/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 20.53 | 90.73 | 25.54 | 19.71 | 78.12 | 34.3 | 24.82 | 64.89 |
| EBITDA 1 | -138.1 | -130.9 | -188.1 | -219.6 | -163.1 | -232.4 | -272.9 | -261.2 |
| EBIT 1 | -140.9 | -134.8 | -193.1 | -226 | -169.2 | -224.5 | -256.1 | -260.1 |
| Operating Margin | -686.39% | -148.61% | -756.13% | -1,146.26% | -216.56% | -654.55% | -1,031.83% | -400.91% |
| Earnings before Tax (EBT) 1 | -133.7 | -116 | -192.5 | -220.4 | -153.2 | -201.3 | -234.6 | -245 |
| Net income 1 | -133.7 | -116 | -192.5 | -220.4 | -153.2 | -206.3 | -242.3 | -248.8 |
| Net margin | -651.43% | -127.82% | -753.61% | -1,118.26% | -196.13% | -601.41% | -976.21% | -383.36% |
| EPS 2 | -2.680 | -1.980 | -2.850 | -3.210 | -2.020 | -2.453 | -2.561 | -2.603 |
| Free Cash Flow 1 | -56.16 | -187 | -171.8 | -181.5 | -136.9 | -194.2 | -230.2 | -259.1 |
| FCF margin | -273.54% | -206.11% | -672.49% | -920.59% | -175.23% | -566.12% | -927.45% | -399.25% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/26/20 | 2/25/21 | 2/24/22 | 2/22/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 6.197 | 12.47 | 6.771 | 6.362 | 0.042 | 6.536 | 9.851 | 2.887 | 5.336 | 60.05 | 7.296 | 5.497 | 5.699 | 14.01 | 7.63 |
| EBITDA 1 | -38.06 | -40.1 | -50.75 | - | - | -61.87 | - | - | -48.65 | -22.5 | -60.46 | -62.23 | -64.18 | - | - |
| EBIT 1 | -39.25 | -41.61 | -50.75 | -54.23 | -57.52 | -63.45 | -50.96 | -44.09 | -50.16 | -23.96 | -55.77 | -56.84 | -59.28 | -54.41 | -58.1 |
| Operating Margin | -633.42% | -333.7% | -749.52% | -852.47% | -136,952.38% | -970.72% | -517.32% | -1,527.33% | -940.09% | -39.9% | -764.29% | -1,033.98% | -1,040.3% | -388.37% | -761.53% |
| Earnings before Tax (EBT) 1 | -39.08 | -41.44 | -50.52 | -53.45 | -55.73 | -60.74 | -49.04 | -40.29 | -45.02 | -18.87 | -45.17 | -50.24 | -52.49 | -47.81 | -55.06 |
| Net income 1 | -39.08 | -41.44 | -50.52 | -53.45 | -55.73 | -60.74 | -49.04 | -40.29 | -45.02 | -18.87 | -46.72 | -51.36 | -53.68 | -50.27 | -55.06 |
| Net margin | -630.66% | -332.31% | -746.05% | -840.19% | -132,680.95% | -929.28% | -497.78% | -1,395.57% | -843.68% | -31.43% | -640.34% | -934.28% | -941.92% | -358.84% | -721.64% |
| EPS 2 | -0.5700 | -0.6100 | -0.7400 | -0.7800 | -0.8100 | -0.8800 | -0.7100 | -0.5600 | -0.5500 | -0.2300 | -0.5783 | -0.6252 | -0.6394 | -0.5922 | -0.6040 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/8/21 | 2/24/22 | 5/4/22 | 8/3/22 | 11/2/22 | 2/22/23 | 5/5/23 | 8/2/23 | 11/3/23 | 2/28/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 457 | 402 | 500 | 437 | 427 | 252 | 95 | 86.7 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -56.2 | -187 | -172 | -181 | -137 | -194 | -230 | -259 |
| ROE (net income / shareholders' equity) | -53.6% | -35.4% | -40.6% | -48.2% | -43.2% | -110% | -193% | -218% |
| ROA (Net income/ Total Assets) | -28.8% | -21.4% | -30.8% | -37% | -30.2% | -83.9% | -174% | -211% |
| Assets 1 | 464.6 | 540.7 | 625 | 595.9 | 506.7 | 245.8 | 139.6 | 117.9 |
| Book Value Per Share 2 | 4.810 | 6.290 | 8.080 | 5.250 | 4.600 | 3.070 | 1.400 | 0.9700 |
| Cash Flow per Share 2 | - | - | -2.420 | -2.580 | -1.790 | -3.280 | -3.150 | - |
| Capex 1 | 6.17 | 7.16 | 7.98 | 4.12 | 4.72 | 5.25 | 5.25 | 4.5 |
| Capex / Sales | 30.04% | 7.89% | 31.23% | 20.89% | 6.04% | 15.31% | 21.15% | 6.93% |
| Announcement Date | 2/26/20 | 2/25/21 | 2/24/22 | 2/22/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
5.32
USD
Average target price
15.4
USD
Spread / Average Target
+189.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -47.48% | 437M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- EDIT Stock
- Financials Editas Medicine, Inc.
